ESMO 2026 — End-of-Day Summary
An abstract digest clustered by tumour group and ranked by clinical priority. Numerical results (HR, PFS, OS, ORR) are preserved verbatim; reliability caveats are embedded within each study's card.
How this digest is organized
- Primary axis — disease group: Each item was clustered by tumour group / official ESMO track (Breast Cancer, Thoracic / Lung Cancer, Gastrointestinal Cancers, Genitourinary Cancers, Gynaecological Cancers, Melanoma & Skin Cancers, Sarcoma, CNS & Rare Tumours, Haematological Malignancies, Developmental Therapeutics & Early Phase, Translational Research & Biomarkers, Public Policy, Access & Health Services).
- Secondary axis — clinical priority: Cards and sections were ranked into three tiers (key below).
- Reliability inside the card: Hedging present in the source (interim, immature, small n, retrospective, non-ESMO data) is placed as a caveat strip inside the relevant card.
- Embargoed titles separated: Late-breaking Plenary / Presidential Symposium abstracts whose results are embargoed until presentation are collected in a dedicated section at the end.
Highlights of the Day
practice-changing findings, ranked🎀 Breast Cancer
13 studiesKEYNOTE-B49 — pembrolizumab + chemo vs placebo + chemo (HR+/HER2− PD-L1+ ABC)
LBA51Indication: 1L CPS≥1 HR+/HER2− ABC after prior ET; 99%+ prior CDK4/6i
Key finding: mPFS 6.7 vs 6.0 mo; HR 0.74 (0.58–0.95), p=0.0089. Final OS: 21.0 vs 22.2 mo; HR 1.04 (0.81–1.33), p=0.6185. CPS≥10 PFS HR 0.59 (0.35–0.98). G≥3 TRAEs 37.6% vs 32.7%.
Clinical relevance: Significant PFS gain but no OS benefit; unlikely practice-changing per expert comment.
No OS benefit; small trial, sample reduced for low PD-L1 prevalence.
Source: ESMO 2026 LBA51 · H.S. Rugo
FOURLIGHT-1 — atirmociclib + fulvestrant vs ICT (HR+/HER2− post-CDK4/6i)
1842OIndication: HR+/HER2− mBC progressing on prior adjuvant/1L CDK4/6i
Key finding: mPFS 9.4 vs 6.6 mo; HR 0.60 (0.440–0.825), p=0.0007. ORR 19.3% vs 11.3%, p=0.0451. mDOR 14.8 vs 9.3 mo. CBR 61.9% vs 46.0%. Neutropenia 46.4%, 4.0% d/c for TRAEs.
Clinical relevance: First next-gen CDK4-selective inhibitor with significant PFS gain after CDK4/6i.
OS immature.
Source: ESMO 2026 1842O · A. Giordano
LBA15 — anbenitamab + HB1801 vs THP (HER2+ advanced BC, 1L)
LBA15Indication: HER2+ advanced BC, no prior chemo/HER2 therapy for advanced disease
Key finding: BIRC mPFS NR (95% CI 24.9, NE) vs 14.3 mo (12.4–16.4); HR 0.46 (0.37–0.56), p<0.0001. Confirmed ORR 87.6% vs 73.4%. mDOR NR vs 16.6 mo. G≥3 TRAEs 36.9% vs 25.3%.
Clinical relevance: May establish a new SOC in HER2+ advanced BC.
Interim analysis; OS immature.
Source: ESMO 2026 LBA15 · B. Xu
LBA14/MA.40/FINER — fulvestrant + ipatasertib vs placebo (ER+/HER2− mBC post-CDK4/6i)
LBA14Indication: ER+/HER2− mBC after CDK4/6i + AI
Key finding: mOS 26.68 vs 25.76 mo; HR 0.97 (0.70–1.33), p=0.83. AKT pathway-altered mOS 23.66 vs 25.23 mo; HR 1.14 (0.72–1.80), p=0.58. No new safety signals.
Clinical relevance: PFS gain did not translate into OS benefit — negative key secondary.
Negative OS despite earlier PFS win.
Source: ESMO 2026 LBA14 · A.D. Redfern
LBA16/VIKTORIA-1 Study 2 — gedatolisib ± palbociclib + fulvestrant vs alpelisib + fulvestrant (PIK3CA MT)
LBA16Indication: HR+/HER2− PIK3CA-mutant ABC
Key finding: Visceral mPFS geda+palbo+fulv 9.8 vs alp+fulv 5.6 mo, HR 0.52 (0.37–0.74); liver mets 9.1 vs 4.6 mo, HR 0.47 (0.31–0.70). Geda+fulv visceral 11.3 vs 5.6 mo, HR 0.53. mDOR 19.4/27.8 vs 7.5 mo. Geda d/c for TEAEs 5.2%/3.8%.
Clinical relevance: Supports geda-based regimens for PIK3CA-mutant ABC.
Source: ESMO 2026 LBA16 · B. Pistilli
LBA96/TROPION-Breast02 — Dato-DXd vs chemo (1L mTNBC with brain mets)
LBA96Indication: 1L locally recurrent/metastatic TNBC, IO not an option; 61 pts with baseline BMs
Key finding: Overall OS HR 0.79 (95.01% CI 0.64–0.98); PFS HR 0.57 (0.44–0.73); confirmed ORR 63% vs 29%. Intracranial responses incl. 1 CR with Dato-DXd.
Clinical relevance: Supports Dato-DXd efficacy irrespective of baseline BMs.
Preliminary intracranial analysis; small BM subgroup.
Source: ESMO 2026 LBA96 · R.A. Dent
LBA26/POP-DURVA — short-course preoperative durvalumab (stage I TNBC)
LBA26Indication: Untreated cT1N0 TNBC with sTILs≥5%
Key finding: pCR 1/71 (1.4%; 0.1–7.2); ORR 11.6%. 41.3% downstaging to pT0/T1a/T1b. Median sTILs +10 points, CPS +9 (p<0.0001); TLS emerged in 33% of baseline-negative; TRAEs 46%, no grade ≥3.
Clinical relevance: Immune remodelling without pCR; baseline sTILs alone insufficient to enrich responders.
Very low pCR; single-arm.
Source: ESMO 2026 LBA26 · J.M. Ribeiro
evERA (2RO) — giredestrant + everolimus vs SOC ET + everolimus biomarkers (ER+/HER2− post-CDK4/6i)
2ROIndication: ER+/HER2− ABC post-CDK4/6i, ctDNA biomarkers
Key finding: PFS HR 0.52 (cTF≥1%) and 0.61 (cTF<1%). ESR1m: cTF≥1% HR 0.45 (0.31–0.65); Y537 HR 0.35; D538 HR 0.58. Benefit across TP53, PIK3CA, RB1 subgroups.
Clinical relevance: GIRE+E PFS benefit maintained across genomic subgroups.
Exploratory analyses.
Source: ESMO 2026 2RO · S.M. Tolaney
postMONARCH (1RO) — abemaciclib + fulvestrant vs placebo + fulvestrant (final OS)
1ROIndication: HR+/HER2− ABC after prior CDK4/6i + ET
Key finding: mOS 32.1 vs 24.6 mo; HR 0.80 (0.60–1.06), p=0.1145 (NS). Updated PFS HR 0.78 (0.62–0.99), nominal p=0.039. No new safety signals.
Clinical relevance: Numerical OS gain but statistical significance not met.
OS not statistically significant.
Source: ESMO 2026 1RO · K. Kalinsky
HER2CLIMB-05 PROs (1766RO) — tucatinib vs placebo + T + P (1L HER2+ mBC maintenance)
1766ROIndication: 1L maintenance HER2+ mBC
Key finding: TTCD GHS/QoL HR 0.81 (0.67–0.99); 14.6 vs 10.3 mo. Physical function TTCD HR 0.73 (0.59–0.89); 17.5 vs 10.6 mo. TTFD PF HR 0.79 (0.65–0.96).
Clinical relevance: QoL preserved/improved with Tuc; supports 1L maintenance role.
Source: ESMO 2026 1766RO · V.C. Dieras
LBA17/PREDICT-HER — HER2-PET imaging to predict T-DXd efficacy (advanced BC)
LBA17Indication: HER2+/HER2-low/zero advanced BC on T-DXd
Key finding: mPFS 13.6 vs 5.1 mo in HER2-PET+ vs HER2-PET−; adj. HR 0.11 (0.05–0.26). NPV 88.2% overall, 100% in HER2-low/zero. PPV 93.8% in HER2+.
Clinical relevance: HER2-PET could refine T-DXd selection beyond IHC.
Single-centre phase II.
Source: ESMO 2026 LBA17 · J. Jin
3RO — 18F-FES PET whole-body ER heterogeneity (ER+/HER2− mBC)
3ROIndication: 1L ET for ER+/HER2− mBC in ET-FES trial
Key finding: At 70.2 mo mFU, 5-y OS 59.6% (concordant) vs 40.9% (discordant); HR 1.79 (1.05–3.03), p=0.04. mOS 71.4 vs 42.5 mo. mPFS 18.1 vs 11.7 mo (HR 1.42, p=0.13).
Clinical relevance: Prognostic role of whole-body ER heterogeneity.
Small subgroup with discordant lesions.
Source: ESMO 2026 3RO · A. Gennari
LBA20 — AI digital pathology for 70-gene recurrence (early breast cancer)
LBA20Indication: Early-stage BC H&E-based 70-gene digital assay
Key finding: Concordance with MammaPrint r=0.954. 10-y BCSS 98.1% (D-Low) vs 86.7% (D-High); HR 0.12 (0.04–0.39), p<0.0001. ER+/HER2− HR 0.10 (0.03–0.36). Independent predictor in MVA.
Clinical relevance: Image-based biomarker to widen access to recurrence-risk stratification.
Source: ESMO 2026 LBA20 · L.J. Van't Veer
🫁 Thoracic / Lung Cancer
11 studiesDeLLphi-305 — tarlatamab + durvalumab vs durvalumab (1L maintenance ES-SCLC)
LBA3Indication: ES-SCLC without progression after 1L durva+EP
Key finding: mOS 21.1 vs 12.7 mo; HR 0.42 (0.32–0.54), p<0.001. mPFS 7.4 vs 1.9 mo; HR 0.34 (0.28–0.42), p<0.001. ORR 26.4% vs 4.1%, p<0.001. CRS 49.6% (G≥3 0.4%); no ICANS G≥3.
Clinical relevance: Potential new SOC 1L maintenance in ES-SCLC.
Source: ESMO 2026 LBA3 · J. Sands
LBA74/DESTINY-Lung04 PROs — 1L T-DXd vs pembro + chemo (HER2m NSCLC)
LBA74Indication: 1L HER2m (exon 19/20) advanced NSCLC
Key finding: TTD cough 26.2 vs 11.0 mo; HR 0.66 (0.44–0.99). Dyspnea HR 0.77 (0.54–1.09); chest pain HR 0.80 (0.54–1.18). PF generally higher with T-DXd from Wk 20 and at EOT.
Clinical relevance: Supports T-DXd as 1L option in HER2m NSCLC.
Primary PFS/safety reported separately.
Source: ESMO 2026 LBA74 · S. Novello
LBA73/PACE-LUNG — ctDNA-guided chemo intensification + osimertinib (EGFRm NSCLC)
LBA73Indication: Untreated EGFRm NSCLC with persistent ctDNA EGFRm at Wk 3
Key finding: 50/255 (19.6%) received CTx. mPFS1 from CTx start 16.3 mo (10.8–18.9); 12-/24-mo PFS 57.8%/21.7%. mPFS0 17.8 mo. mOS1 29.2 mo (23.2–42.4).
Clinical relevance: ctDNA-guided intensification feasible with favorable PFS vs historical data.
Single-arm.
Source: ESMO 2026 LBA73 · M. Sebastian
FLAURA2 ctDNA (2719RO) — on-treatment EGFRm clearance (1L EGFRm NSCLC)
2719ROIndication: 1L EGFRm advanced NSCLC on osi ± plat–pem
Key finding: Wk 3 clearance 81% vs 71%; Wk 6 88% vs 89%. Consistent PFS/OS benefit regardless of clearance (e.g., Wk 3 PFS HR 0.50/0.59; OS HR 0.84/0.65).
Clinical relevance: EGFRm clearance prognostic but not predictive; osi+plat–pem superior regardless.
Exploratory.
Source: ESMO 2026 2719RO · D. Planchard
COCOON SC cohort (2700RO) — SC amivantamab + lazertinib with optimized DM (1L EGFRm NSCLC)
2700ROIndication: 1L EGFRm advanced NSCLC with proactive DM including zinc
Key finding: Grade ≥2 DAEIs by Wk 12: 34% overall (scalp 5%, paronychia 18%). 1 G3 DAEI; no G4–5. Dose reductions 11%, d/c 3%, interruptions 29%.
Clinical relevance: Numerical reduction vs IV ami+laz with standard DM.
No formal comparison; short follow-up.
Source: ESMO 2026 2700RO · B.C. Cho
CROWN ctDNA (2636RO) — resistance mechanisms to 1L lorlatinib (ALK+ NSCLC)
2636ROIndication: 1L advanced ALK+ NSCLC on lorlatinib
Key finding: No new ALK resistance mutations at EOT. Bypass (RTK/RAS/MAPK) and inflammatory/angiogenesis pathways implicated. More baseline alterations in EPs vs LTRs (median 10 vs 6). Baseline TF prognostic; Wk 4/24 TF decrease associated with longer PFS.
Clinical relevance: Supports ctDNA for risk stratification on lorlatinib.
Exploratory; small EOT sample.
Source: ESMO 2026 2636RO · B.J. Solomon
2631RO — BAT8008 (TROP2-ADC) + BAT1308 (anti-PD-1) (1L advanced NSCLC)
2631ROIndication: Treatment-naïve advanced NSCLC
Key finding: ORR 57.9%; DCR 89.5%; 6-mo PFS 64.8% (n=76). G≥3 TRAEs 38.1%; G≥3 stomatitis 7.2%; no new immune signals.
Clinical relevance: Supports planned randomized evaluation.
Single-arm phase 2.
Source: ESMO 2026 2631RO · S.D. Hong
2658RO — telisotuzumab adizutecan (c-MET ADC) OS (NSCLC phase 1)
2658ROIndication: Advanced EGFR WT or MUT NSQ NSCLC post platinum/IO/TKI
Key finding: mOS EGFR WT 13.8 mo (9.0–25.2); EGFR MUT 16.2 mo (11.6–19.9). c-MET ≥3+/≥10% WT: mOS 25.2 mo. ORR 50% (WT) / 63% (MUT). No new safety signals.
Clinical relevance: OS favorable vs chemotherapy or other ADCs in similar settings.
Phase 1 single-arm.
Source: ESMO 2026 2658RO · D. Sommerhalder
1950RO/LK101-IIT02 — personalized neoantigen DC vaccine (1L NSCLC maintenance)
1950ROIndication: Locally adv/metastatic NSCLC on 1L maintenance after chemo-IO
Key finding: ORR 19.0% (4/21), DCR 95.2%. mFU 3.8 mo. 9-mo PFS from 1L start 85.4%. G≥3 TRAEs for LK101 8.0%. Neoantigen-specific T-cell responses in all evaluable.
Clinical relevance: Supports upcoming randomized phase 2.
Small, immature PFS/OS.
Source: ESMO 2026 1950RO · J. Duan
1951RO — pumitamig (PD-L1×VEGF-A) + chemo in SCLC/TNBC with brain mets
1951ROIndication: SCLC and TNBC pts with/without BMs
Key finding: SCLC with BMs: 1L+carbo-eto cORR 77.8% vs 75.9% no BM; icORR confirmed 38.2% (icCR 17.7%). TNBC confirmed icORR 42.9%. Systemic efficacy comparable regardless of BMs.
Clinical relevance: Encouraging intracranial activity.
Small BM subgroups.
Source: ESMO 2026 1951RO · K.N. Franks
1952RO — IBI363 (PD-1/IL-2) + bevacizumab vs docetaxel (IO-resistant LUAC)
1952ROIndication: Locally advanced/metastatic IO-resistant lung adenocarcinoma
Key finding: mPFS 4.4 vs 2.8 mo, p=0.0031; HR 0.45 (0.26–0.77). cORR 15.6% vs 4.8%. 6-mo PFS 40.5% vs 4.0%. 1 treatment-related death in DTX arm.
Clinical relevance: Encouraging early efficacy signal post-IO.
Small randomized phase 1b.
Source: ESMO 2026 1952RO · J. Zhou
⚕ Gastrointestinal Cancers
12 studiesCheckMate 8HW — nivolumab + ipilimumab vs nivolumab or chemo (MSI-H/dMMR mCRC, final OS)
LBA32Indication: MSI-H/dMMR mCRC across lines
Key finding: All lines OS HR 0.61 (0.46–0.82), p=0.0009. 1L vs chemo OS HR 0.37 (0.24–0.57), p<0.0001. 1L NIVO+IPI vs NIVO OS HR 0.66 (0.44–0.99), p=0.0432 (NS). ORR 72–74% vs 58–61% vs 27%.
Clinical relevance: Reinforces NIVO+IPI as 1L SOC in MSI-H/dMMR mCRC.
1L vs NIVO OS not statistically significant.
Source: ESMO 2026 LBA32 · S. Lonardi
LBA31/PRABITAS — biweekly vs conventional FTD/TPI + bevacizumab (refractory mCRC)
LBA31Indication: Refractory mCRC later-line
Key finding: mOS 11.3 vs 10.3 mo; HR 0.93 (0.80–1.08), noninferior. mPFS 3.9 vs 3.9 mo; HR 0.93 (0.81–1.06). G≥3 neutropenia 13% vs 39%; febrile 1% vs 5%; G≥2 anorexia 15% vs 26%, diarrhea 4% vs 10%.
Clinical relevance: New standard biweekly schedule — preserved efficacy, less toxicity.
Source: ESMO 2026 LBA31 · H. Taniguchi
LBA48/EMERALD-3 — tremelimumab + durvalumab ± lenvatinib + TACE (eeHCC)
LBA48Indication: Embolisation-eligible HCC post-hoc by ALBI grade
Key finding: ALBI gr1 mOS 44.6 vs 39.2 mo, HR 0.86 (0.60–1.22); gr2/3 28.5 vs 22.1 mo, HR 0.88 (0.60–1.28). STRIDE+TACE gr1 HR 0.57 (0.36–0.90). PFS2 and TTNT improved across groups. Max G3/4 TRAEs 62–64% vs 18–20%.
Clinical relevance: Supports STRIDE-based regimen + TACE in eeHCC.
Post-hoc exploratory.
Source: ESMO 2026 LBA48 · M. Kudo
LBA21/ACTICCA-1 — adjuvant GemCis vs capecitabine (resected BTC)
LBA21Indication: Resected biliary tract/gallbladder cancer
Key finding: mDFS 2.14 vs 1.49 y, log rank p=0.097. RMST 3-y: +2.6 DFS months with GC (p=0.01). OS trend p=0.076. More SAEs with GC (130 vs 113).
Clinical relevance: Supports GC as adjuvant option in BTC.
Primary endpoint missed by log-rank; RMST positive.
Source: ESMO 2026 LBA21 · H. Wege
459O/COMPANION-002 — paclitaxel ± tovecimig (2L advanced BTC)
459OIndication: Advanced/metastatic BTC after 1L therapy
Key finding: BICR ORR 17.1% vs 5.3%, p=0.031. mPFS 4.7 vs 2.6 mo; HR 0.44, p<0.0001. OS HR 1.05, p=0.78 (confounded by 54% crossover). mPFS2 3.5 vs 1.9 mo; HR 0.36, p=0.0016.
Clinical relevance: Significant PFS/ORR benefit; OS confounded.
OS not improved; high crossover.
Source: ESMO 2026 459O · N.S. Azad
1679O/BGB-B2033 — GPC3×4-1BB BsAb (advanced HCC)
1679OIndication: Advanced HCC, ≥1 prior line
Key finding: Confirmed ORR across doses: 300 mg 28.6%, 600 mg 35.7%, 1000 mg 20.0%, 450 mg 21.7%, 900 mg 16.0%. 6-mo DOR at ≥300 mg 72.7%. G≥3 TRAEs 5%; no G4/5. RP2D 450 mg.
Clinical relevance: Encouraging durability in heavily treated HCC.
Phase 1; short follow-up.
Source: ESMO 2026 1679O · H.J. Chon
787RO/BRICKET — ctDNA-guided EC rechallenge (BRAFV600E mCRC)
787ROIndication: Chemorefractory BRAFV600E mCRC without resistance alterations in ctDNA
Key finding: No objective responses; 6 pts (37.5%) SD, median 2.9 mo. mPFS 2.9 mo; mOS 9.1 mo. 11 (68.8%) died.
Clinical relevance: No activity signal despite ctDNA selection.
Negative efficacy.
Source: ESMO 2026 787RO · M.M. Germani
788RO/ECLYPse — EC beyond progression + FOLFIRI (BRAFV600E mCRC)
788ROIndication: BRAF V600E mCRC progressing on 2L EC after initial response
Key finding: 6-mo PFS 69.5% (51.7–93.6%); mPFS 7.1 mo (6.2–NE). 6/12-mo OS 94.1%/83.7%. No new safety signals.
Clinical relevance: Meets primary endpoint; EC continuation beyond PD plus chemo extends control.
Single-arm, small.
Source: ESMO 2026 788RO · M.A. Calegari
789RO/TRIDENTE — ENCO + BINI + CET rechallenge (BRAFV600E mCRC)
789ROIndication: BRAFV600E mCRC with prior PR to EC + ≥4-mo interval
Key finding: ORR 19.0% (90% CI 6.8–38.4%); 4 PRs. SD 12; tumor shrinkage in 11 (52.4%). mPFS 2.8 mo; mOS 9.6 mo. Without ctDNA resistance alterations ORR 25.0% vs 12.5%.
Clinical relevance: Positive activity signal; endpoint met.
Small single-arm.
Source: ESMO 2026 789RO · D. Kotani
790RO/QTX3034 — G12D-preferring KRAS inhibitor + cetuximab ± mFOLFOX6 (KRAS G12D CRC)
790ROIndication: KRAS G12D-mutant CRC post oxaliplatin/irinotecan
Key finding: At RP2D 1200 mg (n=19) ORR 26%, DCR 79%. mFOLFOX6 combo 800 mg: 2/4 responses. G3 AEs 25%; 1 (3%) d/c for AE.
Clinical relevance: First KRAS inhibitor + cetux ± chemo signal in CRC G12D.
Early phase.
Source: ESMO 2026 790RO · I. Garrido-Laguna
791RO — telisotuzumab adizutecan + bevacizumab (3L+ CRC, updated)
791ROIndication: 3L+ CRC randomized vs TAS-102 + bev
Key finding: Temab-A 2.4 mg/kg + bev: cORR 30.0%, mPFS 6.8 mo, mOS 14.7 mo vs SOC mOS 10.2 mo (HR 0.62). 15-mo OS 0.5 vs 0.3.
Clinical relevance: Supports phase 3 AndromMETa-560.
Phase 1 randomized small.
Source: ESMO 2026 791RO · M. Cecchini
LBA18/BEAGLE-MDT — AI decision support for colorectal MDT
LBA18Indication: Colorectal cancer MDT decision-making
Key finding: 15 synthetic cases, 5 clinicians: patient summarisation mean 4.50–5.00 (73–100% 5/5); management 4.07–4.87 (40–87% 5/5); trial-matching 4.33–4.93 (67–93% 5/5).
Clinical relevance: Technical feasibility; prospective validation needed.
Synthetic cases; not clinical effectiveness.
Source: ESMO 2026 LBA18 · S. Ashraf
🔷 Genitourinary Cancers
14 studiesLBA2/VOLGA — perioperative durvalumab ± tremelimumab + neoadjuvant EV (MIBC)
LBA2Indication: Cisplatin-ineligible/refusing MIBC
Key finding: D+EV vs control EFS HR 0.51 (0.38–0.67), p<0.0001; 24-mo EFS 64% vs 45%. OS HR 0.58 (0.40–0.83), p=0.0027. pCR 45% vs 10%. D+T+EV EFS HR 0.61 (0.47–0.80), p=0.0004. Max G3/4 TRAEs 30%/42%.
Clinical relevance: Dual primary endpoints met; D+EV also significantly improves OS.
D+T+EV OS not significant.
Source: ESMO 2026 LBA2 · T.B. Powles
LBA4/DASL-HiCaP — darolutamide + ADT + RT (very high-risk localised PC)
LBA4Indication: Very high-risk localised or biochemically persistent/recurrent PC after RP
Key finding: 4-y MFS-CI 95% vs 88%; HR 0.42 (0.27–0.66), p=0.0001. PSA-PFS HR 0.47 (0.33–0.67); PCSS HR 0.58; OS HR 0.88 (0.49–1.59). G≥3 AEs 43% vs 36%.
Clinical relevance: Significant MFS gain supports treatment intensification.
OS immature.
Source: ESMO 2026 LBA4 · T. Niazi
PEACE-1 (2215O) — abiraterone + SOC vs SOC (de novo mCSPC, long-term)
2215OIndication: De novo mCSPC, 57% high-volume
Key finding: mOS 5.7 vs 4.6 y; HR 0.75 (0.65–0.87), p=0.0001. ADT+DOC subgroup +abi mOS 6.2 vs 4.4 y; HR 0.68 (0.56–0.82). High-volume 8-y OS 38% vs 20%. Benefit independent of volume (interaction p=0.56).
Clinical relevance: Confirms triplet ADT+DOC+abiraterone benefit long term.
Source: ESMO 2026 2215O · K. Fizazi
LBA53/PROTEUS substudy — perioperative APA + ADT vs RP alone (high-risk localised PC)
LBA53Indication: cN0/N1 high-risk localised or locally advanced PC undergoing RP+PLND
Key finding: Primary met: mEFS NR vs 19.1 mo; HR 0.38 (0.26–0.55), p<0.0001. MFS HR 0.49 (0.26–0.90). Subsequent tx HR 0.29 (0.20–0.43). G3/4 AEs 30.7% vs 21.7%.
Clinical relevance: APA+ADT superior to RP alone across EFS, MFS, time to subsequent tx.
Source: ESMO 2026 LBA53 · A. Briganti
2216O/JNJ-6143 — oral AR RIPTAC (mCRPC/mAPMR phase 1)
2216OIndication: mCRPC/mAPMR after ≥1 ARPI
Key finding: n=52; median 6 prior lines. 50 mg (n=17): confirmed PSA50 71%, PSA90 41%; 5/7 measurable PR (4 confirmed). PSA50 across high-risk subsets. G≥3 TRAEs 10%; 1 G≥3 TRAE at 50 mg.
Clinical relevance: First-in-class active in heavily pretreated high-risk mCRPC.
Early phase.
Source: ESMO 2026 2216O · B. Garmezy
2045O — Decipher score and ARPI benefit (very high-risk PC)
2045OIndication: Non-metastatic PC on ADT in STAMPEDE and RWD cohort (n=12,361 RWD, 401 STAMPEDE)
Key finding: RWD: per 0.1 Decipher ↑ DM aHR 1.34–1.39; OS aHR 1.23. STAMPEDE: DM aHR 1.44 (1.19–1.76); OS aHR 1.28 (1.14–1.45). 5-y DM benefit of AAP 2/12/8% in low/high/very-high score; interaction p=0.03.
Clinical relevance: Decipher improves prediction and refines AAP benefit in very high-risk PC.
Source: ESMO 2026 2045O · S. Howlett
4737RO/POTOMAC — durvalumab + BCG I+M in papillary-only high-risk NMIBC
4737ROIndication: BCG-naïve high-risk NMIBC, papillary only tumours
Key finding: High-risk events 28/217 vs 44/220; early events 57% vs 66%. BCG-unresponsive 61% vs 88%. Time to cystectomy HR 0.51; cystectomy-free survival HR 0.59. Max G3/4 TRAEs 23% vs 3%.
Clinical relevance: Supports D+BCG I+M for papillary-only high-risk NMIBC.
Post hoc exploratory.
Source: ESMO 2026 4737RO · M. De Santis
4738RO/KEYNOTE-B15/EV-304 PROs — perioperative EV + pembro vs cis+gem (MIBC)
4738ROIndication: Cisplatin-eligible MIBC perioperative
Key finding: Wk 42 CFBL similar across arms. TTD GHS/QoL HR 0.84, PF 0.88, RF 0.80; BCI bowel 1.11, urinary 0.93, sexual 1.17. BCI sexual worsened in both arms.
Clinical relevance: HRQoL preserved; supports EV+pembro benefit–risk.
Source: ESMO 2026 4738RO · A. Gomez de Liano Lista
4741RO/NIAGARA — molecular subtypes and perioperative D + NAC (MIBC)
4741ROIndication: Cisplatin-eligible MIBC
Key finding: ITT 24-mo EFS 68% vs 60%; HR 0.68 (0.56–0.82). Benefit across TP53 (HR 0.51), FGFR3 (0.24), TMB-high (0.44), basal-squamous (0.47), luminal (0.52); luminal-papillary HR 1.35.
Clinical relevance: Broad benefit across molecular subgroups except luminal-papillary.
Exploratory, non-alpha-controlled.
Source: ESMO 2026 4741RO · M.D. Galsky
4739RO/2870-002 — Sac-TMT (TROP2 ADC) + pembro (1L cis-ineligible la/mUC)
4739ROIndication: Treatment-naïve cis-ineligible la/mUC
Key finding: n=40, mFU 20.5 mo. cORR 68%. mDOR 19.4 mo. mPFS 11.2 mo (5.8–NR). mOS NR. G3/4 TRAEs 60%. No fatal TRAEs.
Clinical relevance: Supports phase 3 development in UC.
Small single-arm phase 2.
Source: ESMO 2026 4739RO · X. Bian
4740RO/EV-103 — EV ± pembrolizumab long-term (1L cis-ineligible la/mUC)
4740ROIndication: Cis-ineligible 1L la/mUC
Key finding: EV+P mDOR 29.6 mo; mPFS 10.4 mo; mOS 27.7 mo. 60-mo OS 33%; 84-mo 28.2%. G≥3 TRAEs 64.5% vs 47.9%.
Clinical relevance: Reinforces favorable long-term benefit–risk.
Source: ESMO 2026 4740RO · J.P. Maroto Rey
4748RO — neoadjuvant disitamab vedotin + gemcitabine (HER2 2/3+ MIBC)
4748ROIndication: T2–T4aNxM0 MIBC with HER2 2+/3+, cisplatin-ineligible/refusing
Key finding: pCR 62.5% (15/24); 3-cyc 40% vs 4-cyc 78.6%. At 27 mo mFU: 2-y EFS 88.0%, 3-y 53.3%. No G>3 TRAEs during neoadj.
Clinical relevance: Chemo-sparing HER2-directed neoadjuvant option.
Single-arm.
Source: ESMO 2026 4748RO · C. Yang
4749RO/WUTSUP-02 — tislelizumab + disitamab vedotin perioperative (UTUC)
4749ROIndication: Localized high-risk/locally advanced UTUC
Key finding: pCR 28.2% (11/39); ORR 79.5%. HER2 2+/3+ pCR 31.3%, ORR 87.5%. 2-y OS 87.1%, MFS 83.9% at 24 mo mFU.
Clinical relevance: Encouraging perioperative activity in UTUC.
Single-arm phase 2.
Source: ESMO 2026 4749RO · Y. Bao
4757RO/GDFather-NEO — nivolumab ± visugromab (MIBC)
4757ROIndication: Cisplatin-ineligible/refusing cT2–T4aN0M0 MIBC
Key finding: pCR 33.3% vs 7.7%; MPR 60.0% vs 23.1%; ORR 60.0% vs 15.4%. 14.6-mo mFU: 11/12 responders recurrence-free; 4/4 pCR after re-TURBT only in N/V.
Clinical relevance: Supports GDF-15 as resistance target.
Small blinded phase 2.
Source: ESMO 2026 4757RO · A. Necchi
🌸 Gynaecological Cancers
9 studiesLBA38/BEATcc — atezolizumab + CT + bev (1L R/M cervical cancer, final OS)
LBA38Indication: Metastatic/persistent/recurrent cervical cancer, 1L
Key finding: mOS 31.9 vs 22.7 mo; HR 0.69 (0.54–0.88). 4-y OS 40% vs 26%. PFS2 HR 0.62 (0.49–0.78). PD-L1+ OS HR 0.71; PD-L1− HR 0.53.
Clinical relevance: Sustained OS benefit regardless of PD-L1.
Source: ESMO 2026 LBA38 · A. Oaknin
1240O — iparomlimab + tuvonralimab (QL1706) + chemo ± bev (1L R/M cervical)
1240OIndication: Persistent/recurrent/metastatic cervical cancer 1L
Key finding: mPFS 12.35 vs 7.75 mo; HR 0.64 (0.51–0.81), p=0.0001. mOS 30.95 vs 21.78 mo; HR 0.73 (0.57–0.93), p=0.0101. G≥3 TRAEs 80.6% vs 75.9%.
Clinical relevance: Significant PFS and OS gains in cervical cancer.
Source: ESMO 2026 1240O · J. Liu
1239O/NRG-GY020 — RT ± pembrolizumab (early-stage HIR dMMR endometrial)
1239OIndication: Newly diagnosed HIR dMMR endometrioid EC
Key finding: RFS3 73% RT vs 70% RT+pembro; standardised Z=-0.48, p=0.68. KM 3-y RFS 81% vs 88%; HR 0.72 (0.33–1.61), p=0.21. 3-y OS 96% both arms. G3/4 toxicity 15% vs 43%.
Clinical relevance: RT alone remains standard; pembro did not meet superiority.
Negative primary endpoint.
Source: ESMO 2026 1239O · F. Backes
LBA36/ENGOT-en11/GOG-3053/KEYNOTE-B21 — ctDNA + pembro in dMMR EC adjuvant
LBA36Indication: Resected high-risk dMMR EC adjuvant SOC + pembro vs placebo
Key finding: IA4 DFS HR 0.34 (0.17–0.65); DSFS HR 0.25 (0.11–0.54). BL ctDNA+ 20%; pembro arm higher clearance (Stage2 20% vs 14%). ctDNA modest predictive value for DSFS.
Clinical relevance: Confirms large pembro benefit in dMMR EC; ctDNA emerging biomarker.
Low event rates limit ctDNA PPV.
Source: ESMO 2026 LBA36 · L. Bodnar
LBA37/DUO-E/GOG-3041/ENGOT-EN10 — interim OS (a/rEC)
LBA37Indication: 1L advanced/recurrent endometrial cancer
Key finding: ITT CP+D vs CP mOS 40.7 vs 39.6 mo, HR 0.87 (0.68–1.11), p=0.259. CP+D+O mOS 51.1 vs 39.6 mo, HR 0.77 (0.60–0.98), p=0.037. dMMR CP+D+O HR 0.43. pMMR HR 0.85.
Clinical relevance: Favorable interim OS with CP+D+O; CP+D not statistically significant.
Interim 52% maturity; p=0.037 nominal.
Source: ESMO 2026 LBA37 · S.N. Westin
LBA40/ZW191 — FRα-targeted ADC (platinum-resistant OC)
LBA40Indication: Platinum-resistant OC heavily pretreated
Key finding: Excl. clear cell: ORR 58% at both 6.4 and 9.6 mg/kg (confirmed 52% and 45%); DCR 100%/92%. All PROC ORR 53%. G≥3 neutropenia 8%/23%; anemia 8%/14%.
Clinical relevance: Strong activity regardless of prior mirvetuximab/PARPi.
Early phase.
Source: ESMO 2026 LBA40 · J.-Y. Lee
1245RO/FONTANA — torvutatug samrotecan (FRα ADC) (PROC)
1245ROIndication: PROC dose escalation/expansion
Key finding: 1.6–2.4 mg/kg (n=143) overall cORR 56.6%. FRα-high 61.7%, low 57.1%, ultralow/null 40.0%. G3/4 neutropenia 25.6%; d/c 8.1%.
Clinical relevance: Informs phase 3 TREVI-OC-01.
Source: ESMO 2026 1245RO · F. Meric-Bernstam
LBA41/BEHOLD-1 — mocertatug rezetecan (B7-H4 ADC) (PROC)
LBA41Indication: PROC dose selection
Key finding: At 5.8 mg/kg: confirmed ORR 62%; mDoR 12.2 mo; mPFS 11.1 mo. G≥3 TRAEs 71% at 5.8 mg/kg (47% all doses). Discontinuation 3%.
Clinical relevance: Supports 5.8 mg/kg for expansion.
Source: ESMO 2026 LBA41 · V. Salutari
1247RO/REJOICE-Ovarian02 — R-DXd + bevacizumab (PROC)
1247ROIndication: PROC after 1–3 prior lines
Key finding: Confirmed ORR 4.8 mg/kg 80% (8/10), 5.6 mg/kg 53% (8/15). All DCR; no DLTs. 1 G5 adjudicated drug-related ILD at 5.6 mg/kg.
Clinical relevance: Promising activity across both doses.
Early phase; small cohorts.
Source: ESMO 2026 1247RO · A. Oaknin
☀ Melanoma & Skin Cancers
2 studiesINTerpath-001 — intismeran autogene + pembrolizumab vs placebo + pembrolizumab (adjuvant stage IIB–IV melanoma)
LBA1Indication: Resected stage IIB/IIC or III/IV cutaneous melanoma
Key finding: 24-mo RFS 82.2% vs 70.0%; HR 0.58 (0.45–0.75), p<0.001. 24-mo DMFS 88.5% vs 80.2%; HR 0.62 (0.45–0.85), p=0.002. G≥3 AEs 23.6% vs 20.3%.
Clinical relevance: First positive phase 3 of individualized mRNA neoantigen therapy.
OS immature.
Source: ESMO 2026 LBA1 · G.V. Long
1955RO/IMA402 — PRAME TCER (advanced solid tumors)
1955ROIndication: HLA-A*02:01+ R/R solid tumors, mostly melanoma/OC
Key finding: RP2D ≥10 mg; cORR at RP2D range 30% (6/20); DCR 65%. Melanoma cORR 29% (4/14) incl. 2 CRs. OC 2/3 confirmed responses. G1 CRS 33%; G≥3 CRS 1%. No ICANS or G5.
Clinical relevance: Encouraging activity in heavily pretreated melanoma/OC.
Phase 1; small numbers.
Source: ESMO 2026 1955RO · D. Schadendorf
🧠 Sarcoma, CNS & Rare Tumours
4 studiesLBA89/TANGENT — emactuzumab vs placebo (TGCT)
LBA89Indication: Symptomatic tenosynovial giant cell tumours
Key finding: ORR RECIST 29.7% vs 2.2% (Δ27.8, p<0.001); ORR TVS 53.8% vs 6.7% (Δ47.8, p<0.001). PROMIS-PF +4.3 vs -1.3 (p<0.001); passive ROM +9.93 vs +2.12 (p<0.001). Pain -2.5 vs -0.4.
Clinical relevance: Short-course (5 infusions over 8 wks) effective new option.
Source: ESMO 2026 LBA89 · H. Gelderblom
3714O/HH2853 — EZH1/2 inhibitor (epithelioid sarcoma)
3714OIndication: R/R advanced epithelioid sarcoma
Key finding: ORR 40.0% (BIRC); DCR 77.3%; mDoR 15.6 mo (7.5–NE); mPFS 13.1 mo (7.4–16.6); mOS NR. G≥3 anemia 12.8%, lymphopenia 11.7%.
Clinical relevance: Statistically superior ORR vs historical controls.
Source: ESMO 2026 3714O · X. Niu
3715O/zolucatetide — β-catenin:TCF inhibitor (desmoid tumors)
3715OIndication: Desmoid tumors treatment-naïve or R/R
Key finding: n=38; DCR 100%. In 19 pts >1 scan: ORR 74% (1 CR). G≥3 hyperbilirubinemia 7.9%. No d/c for AE or PD.
Clinical relevance: Rapid response and high ORR in desmoid.
Small, early phase.
Source: ESMO 2026 3715O · M. Gounder
3716O/SELNET 7.2 — cirtuvivint (TRS)
3716OIndication: Advanced TRS progressing after anthracycline
Key finding: 3-mo PFS 50% overall (32–68%); SFT subset 77% (54–100%). Best ORR 65.5% SD, 34.5% PD. G3/4 neutropenia 24.1%.
Clinical relevance: Positive signal specifically in SFT.
Small, exploratory.
Source: ESMO 2026 3716O · J. Martin-Broto
🩸 Haematological Malignancies
6 studies1454O/Bela-DRd — belamaf + DRd (TI NDMM)
1454OIndication: Transplant-ineligible newly diagnosed myeloma
Key finding: Part 1: ORR 91.7%, ≥CR 70%, MRD-neg 13/16 (81.3%). Part 2 RP2D: ORR 91.7%, MRD-neg 5/7 (71.4%); 18-mo PFS 91.7%/87.5%. 3 fatal TEAEs in part 1.
Clinical relevance: Q2–3-month belamaf with Rd+dara shows deep responses.
Small phase 1/2.
Source: ESMO 2026 1454O · M.A. Dimopoulos
1455O/BelaRd — belantamab mafodotin + Rd (TI NDMM, long-term)
1455OIndication: TI NDMM frail/intermediate-fit
Key finding: ORR 97.6%; sCR 35.7%, CR 14.3%. MRD-neg part1 50%, part2 40%. 18-/24-mo PFS 82.9%/74.9%. Predicted mPFS 83.7–101.8 mo. 8 fatal TEAEs; no d/c.
Clinical relevance: Durable deep responses at RP2D.
Source: ESMO 2026 1455O · I. Ntanasis-Stathopoulos
1456O/LBL-034 — GPRC5D/CD3 BsAb (RRMM)
1456OIndication: Heavily pretreated RRMM
Key finding: mPFS 15.8 mo; 400–1200 µg/kg ORR 82.5%, ≥CR 57.5%, 18-mo PFS 58.0%. EMD ORR 75.0%, mPFS 11.5 mo. G≥3 TRAEs 83.9%; G≥3 CRS 1.8%; no G≥3 ICANS.
Clinical relevance: Durable activity incl. EMD.
Phase 1.
Source: ESMO 2026 1456O · X. Dou
1457O — rocbrutinib + R-CHOP (untreated B-cell lymphoma)
1457OIndication: Untreated B-cell lymphoma; mainly non-GCB DLBCL
Key finding: In 15 DLBCL pts: ORR 100.0%, CR 86.7%. 8/8 ctDNA MRD-neg at CR. No DLTs; G≥3 leukopenia/neutropenia 72.7%. No atrial fibrillation or severe hemorrhage.
Clinical relevance: High CR and MRD-neg rates in non-GCB DLBCL.
Small, early.
Source: ESMO 2026 1457O · Q.Q. Cai
1458O/TRS005 — anti-CD20 ADC (t-DLBCL)
1458OIndication: Transformed DLBCL ≥2 prior lines
Key finding: In 28 evaluable t-DLBCL: ORR 50.0% (30.7–69.4), DCR 71.4%. mPFS 8.67 mo; mDOR 12.91 mo; mOS 19.29 mo. At RP2D 1.8 mg/kg (n=24): ORR 50.0%, mPFS 9.43, mOS 17.08 mo. G≥3 neutropenia 58.1%.
Clinical relevance: Durable responses in t-DLBCL.
Small phase 1 subset.
Source: ESMO 2026 1458O · Y.-K. Shi
1459O/LYT-200 — anti-galectin-9 ± HMA/VEN (R/R HR-MDS/AML)
1459OIndication: R/R HR-MDS post-HMA failure and R/R AML
Key finding: HR-MDS CC at RP2D (n=11 eval): CR 27.3%, ORR 45.5%; 2 MRD-neg bridged to transplant. R/R AML at RP2D (n=26): composite CR 30.8%, PR 7.7%, ORR 42.3%, 19.2% bridged to transplant. No DLTs or treatment-related deaths.
Clinical relevance: Activity in HMA-failure HR-MDS and VEN-exposed AML.
Early phase.
Source: ESMO 2026 1459O · G. Koehne
🧪 Developmental Therapeutics & Early Phase
8 studiesLBA52/iNATURE — personalized neoantigen vaccine + CLERT (R/R solid tumors)
LBA52Indication: Metastatic solid tumors (mostly lung) progressed after ≥1 line
Key finding: mPFS 10.3 vs 3.1 mo; HR 0.29 (0.12–0.71), p=0.007. Neoantigen-specific T-cell responses 83.3%; antibody responses 100%. 2/16 >30% shrinkage. No G≥3 vaccine-related AEs.
Clinical relevance: Significant PFS gain in refractory solid tumors.
Small (n=35); mostly NSCLC.
Source: ESMO 2026 LBA52 · F.P. Kong
999O — elfetabart drozuntecan (B7H3 ADC) + pumitamig (PD-L1×VEGF-A) (advanced solid tumors)
999OIndication: Advanced solid tumors across 4 dose combos
Key finding: 67 evaluable: unconfirmed ORR 36%, DCR 90%, mTTR 1.3 mo. HNSCC ORR 57%; cervical ORR 50%; HCC ORR 28%. G≥3 TRAEs 27%; irAEs 7%; no ILD/pneumonitis.
Clinical relevance: Encouraging activity across tumour types incl. prior IO/bev.
Early phase; short median FU 3 mo.
Source: ESMO 2026 999O · Y. Guo
1000O/HS-20122 — EGFR/cMET bispecific ADC (solid tumors)
1000OIndication: Advanced solid tumors, mostly EGFRm NSCLC post TKI
Key finding: EGFRm NSCLC (n=59 eval) ORR 52.5%, DCR 96.6%. AGA-neg NSCLC ORR 25.0%. NPC ORR 75.0%. CRC 33.3%. G≥3 TRAEs 35.5%; no G≥3 rash; 1 G1 ILD.
Clinical relevance: Favorable safety and activity in EGFRm NSCLC.
Phase 1 single-arm.
Source: ESMO 2026 1000O · H. Zhao
1001O/IBI3001 — EGFR/B7H3 BsADC (solid tumors)
1001OIndication: Advanced solid tumors post-standard therapy
Key finding: ORR 28.0% overall; EGFR-mut NSCLC ORR 31.3%, mPFS 7.0 mo; SCLC ORR 66.7%; biomarker+ ORR 87.5%. G≥3 TRAEs 47.4%; 1 G2 pneumonitis.
Clinical relevance: Encouraging activity, particularly biomarker-positive.
Phase 1.
Source: ESMO 2026 1001O · F. Zhang
1953RO/CS2009 — PD-1/VEGF/CTLA-4 trispecific (mCRC)
1953ROIndication: MSS mCRC later-line and 1L + XELOX
Key finding: Later-line mono 30 mg/kg (n=14): ORR 25%, DCR 87.5%; G≥3 TRAEs 14.3%. 1L + XELOX (n=14): G≥3 TRAEs 14.3%; high response rate reported.
Clinical relevance: Promising activity in MSS mCRC.
Very early phase.
Source: ESMO 2026 1953RO · F. Wang
1954RO/INCA33890 — TGFβR2×PD-1 BsAb + SOC (MSS CRC)
1954ROIndication: MSS CRC combined with FOLFOX/FOLFIRI/bev/cetux
Key finding: 1L FOLFOX+bev ORR 64.9%, DCR 100%. 2L FOLFIRI+bev ORR 50%. 3L+ bev ORR 25%, DCR 42.9%. G≥3 irAEs 6.8%. No DLTs.
Clinical relevance: Encouraging activity in IO-insensitive MSS CRC.
Phase 1 small cohorts.
Source: ESMO 2026 1954RO · S.R. Chandana
1002O/SL-28 — allogeneic leukocyte therapy (stage IV solid tumors)
1002OIndication: 10 evaluable stage IV solid tumors post 1L/2L
Key finding: ORR 100% (CR 20%, PR 60%, SD 20%); bone met resolution 3/3 at median 2.1 mo. Longest DOR >18 mo. No GvHD/CRS.
Clinical relevance: Early signal for off-the-shelf leukocyte therapy.
Very small n=10 interim; no comparator.
Source: ESMO 2026 1002O · G. Tetz
1003O/IM96 — GCC CAR-T (advanced CRC)
1003OIndication: GCC+ mCRC ≥3 prior lines
Key finding: n=12; ORR 42% (5/12); 20×10^8 cohort 50% ORR; liver mets ORR 43%. G3 CRS 1 pt; G3 diarrhea 66%, rash 42%. No treatment-related deaths.
Clinical relevance: Supports 20×10^8 dose for expansion.
Early phase.
Source: ESMO 2026 1003O · L. Chang
🧬 Translational Research & Biomarkers
3 studies170O/RADIANT — radiotherapy foundation model
170OIndication: Multi-tumour RT planning and outcomes
Key finding: Hold-out: GTV Dice 83.52%, CTV 81.53%. Validation AUCs 0.72 oesophageal pCR, 0.84 rectal CR, 0.78–0.81 radiation pneumonitis. C-indices OS 0.73–0.79, PFS 0.71–0.78.
Clinical relevance: Scalable AI framework for RT workflows.
Prospective and multi-centre validation partly retrospective.
Source: ESMO 2026 170O · Z. Zhang
LBA19/ALLIANCE — LLM-assisted chemo side-effect management
LBA19Indication: Breast/CRC pts starting ≥3 mo chemo
Key finding: LLM used at 47.5% visits. AEs recorded nearly doubled (150 vs 78; 5.4 vs 2.8/pt, p=0.006). Hallucination mild at 3 uses, absent at 44. Dose reductions unchanged. Adjusted GHS at EoT -18.4 (-31.2 to -5.5).
Clinical relevance: Useful for toxicities without routines; no QoL benefit shown.
Interim; small (n=56); EoT QoL numerically worse.
Source: ESMO 2026 LBA19 · Y.-J. Kang
1248RO/BEHOLD-1 — biomarkers of response to Mo-Rez (PROC)
1248ROIndication: PROC phase 1b expansion
Key finding: B7-H4 expressed in 96%; not associated with response. TNFα-NF-κB top enriched (NES=2.6). Matrix remodelling signature p=0.00065 for response; CTSB higher in responders (p=0.02).
Clinical relevance: Composite biomarkers beyond target expression needed.
Exploratory.
Source: ESMO 2026 1248RO · S. Lheureux
🌍 Public Policy, Access & Health Services
9 studies3316RO — Clinical development, regulatory and reimbursement duration (cancer vs non-cancer drugs)
3316ROIndication: Approvals 2014–2024 in US, FR, DE, CH
Key finding: Median time to reimbursement: cancer 7.9 vs non-cancer 10.2 y (US); 10.8 vs 11.1 (FR); 7.5 vs 9.5 (DE); 9.3 vs 10.1 (CH). Expedited approvals: cancer 91% vs non-cancer 61% (US).
Clinical relevance: Cancer drugs reach reimbursement faster, mainly via shorter clinical development.
Source: ESMO 2026 3316RO · S. Hediger
3317RO — Treatment costs for essential cancer medicines in 82 countries
3317ROIndication: 64 essential cancer medicines, 222 indications
Key finding: Median tx cost difference HIC vs LMIC US$174 overall; within LMICs US$253; originators US$2,167 (HIC vs LMIC) and US$4,511 (within LMIC). 12/17 LMICs higher medians than 38/44 HICs.
Clinical relevance: Within-group variation often exceeds between-group variation.
Source: ESMO 2026 3317RO · C. Herrle
3318RO — Economic burden of premature lung cancer mortality (185 countries)
3318ROIndication: GLOBOCAN 2022 productivity losses
Key finding: Global losses US$88.2 billion; 87.8 YPLL/100,000. Median losses US$4.0M (low-income) vs US$184.6M (high-income), p<0.001. GDP share 0.034% vs 0.070%, p=0.022.
Clinical relevance: Highlights inequalities and unpaid work burden.
Modelling study.
Source: ESMO 2026 3318RO · N. Libonati
3319RO/EUonQoL — sociodemographic drivers of QoL in European cancer pts
3319ROIndication: 4,302 participants, 32 European countries
Key finding: Vulnerable socioeconomic cluster vs advantaged: H&QoL -4.1, PF -5.9, EF -3.3, SF -3.1 (all significant). Risky lifestyle vs healthy: H&QoL -2.9, PF -4.4. Female vs male PF -2.4, EF -2.6.
Clinical relevance: Identifies vulnerable profiles for European cancer policies.
Source: ESMO 2026 3319RO · C. Brunelli
3320RO — Cervical and lung cancer inequalities in EU-27
3320ROIndication: ECIS 2024 EU-27
Key finding: 25,635 preventable excess cases (14,649 women). Cervical incidence varies 6.4-fold; lung 3-fold. Excess: +2,475 cervical in Romania; +3,069 lung women in Netherlands; +3,934 lung men in Poland.
Clinical relevance: Quantifies inequalities and preventable burden.
Source: ESMO 2026 3320RO · D. Serraino
3321RO — Cost-effectiveness of 1L chemo-IO in solid tumors (systematic review)
3321ROIndication: 64 CEAs, 82 ICER estimates, 6 tumour types
Key finding: Median ICER US$281,259/QALY; WTP US$103,212. Cost-effective: 27% HIC vs 8% LMIC. S1 (CT→ICI maintenance) median US$114,336 vs S2/S3 US$388,784/US$389,690.
Clinical relevance: CT followed by ICI maintenance most favorable economically.
Source: ESMO 2026 3321RO · J. Canzian
3322RO — OS maturity of perioperative/adjuvant ICI approvals
3322ROIndication: 10 phase III trials 2021–2025
Key finding: Median OS event rate at approval 21% (IQR 16–34%). Only 2/10 significant OS at approval; 7 immature. 7/9 NCCN Cat 1 despite non-significant OS. Median time to first OS update 28 mo.
Clinical relevance: Highlights gap between evidence maturity and guideline strength.
Source: ESMO 2026 3322RO · A. Mittal
3323RO — CSO checklist adherence in EMA lung cancer approval trials
3323ROIndication: 31 phase III EMA lung cancer approval trials 2020–2025
Key finding: Median adherence 57.1%. Comparator fully met 25/31; OS/surrogate 12/31; HRQoL 9/31. HRQoL abstract summaries, patient involvement, ESMO-MCBS, cost/resources absent in 31/31.
Clinical relevance: Patient-centred and benefit-contextualisation gaps.
Single-review scoring.
Source: ESMO 2026 3323RO · J.D. Benitez Fuentes
3324RO/EORTC — qualitative analysis of informed consent reviews
3324ROIndication: EORTC PISICs from 49 studies 2014–2024
Key finding: 125 reviews, 1,669 comments, 398 codes, 8 themes incl. clarity, procedures/burdens, risks, data use, patient rights, communication, post-trial.
Clinical relevance: Actionable guidance to improve consent documents.
Source: ESMO 2026 3324RO · I. Shakhnenko
📋 Program Sessions — Invited Talks
no abstractsThis report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.